According to 13th St Gallen International Breast Cancer Conference classification, seventeen patients relapsed as luminal B-like disease (HR+, HER2-, Mib1 ≥ 20%), and eight were luminal A-like BCs (HR+, Mib1 <20%). Here, ERBB2 is linked to breast carcinoma.